In a report issued August 5, Maxim Group analyst Jason Kolbert provided an optimistic view on Teva Pharmaceuticals (TEVA) following the release of the company’s second-quarter results, …
In a research note published yesterday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Cesca Therapeutics (KOOL) with a $7 price target, on …
Maxim Group analyst Jason Kolbert provided an optimistic view on Omeros Corp. (OMER) heading into the company’s second-quarter earnings report, where it is …
In a research report published today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Medivation (MDVN) with a $112 price target. The report follows Medivation’s partner Astellas (ALPMY) second quarter results that included US …
In a research report published today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Pluristem Therapeutics (PSTI) with a $8 price target, which represents a potential upside of 176% from …
In a research report released July 21, Maxim Group analyst Jason Kolbert reaffirmed a Hold rating on IntelliPharmaCeutics (IPCI) with a $3 price target. The analyst commented: “IPCI reported the quarter last …
In a research report published Friday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Synthetic Biologics (SYN) with a $6 price target, which …
In a research report issued yesterday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Inovio Pharmaceuticals (INO) with an $18 price target, …
In a research report released Friday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Gilead Sciences (GILD) with a price target …
In a research note issued today, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Agenus Inc. (AGEN) and a price target of $11, after AGEN announced the final data set …
